In 2012, the Substance Abuse and Mental Health Service Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP) began a project designed to address underage drinking (ages 12-17) and prescription drug misuse (ages 12-25) in high-risk communities using the Strategic Prevention Framework.
In Illinois, underage drinking was identified as a significant issue as early as 2004 through an assessment process conducted by the State Epidemiological Outcomes Workgroup (SEOW). It has continued to be a significant issue for the state through subsequent assessments in 2008 and 2012. Illinois was awarded the SPF-PFS grant in October of 2014 through a grant application submitted by the Illinois Department of Human Services (IDHS).
The SPF-PFS grant provided an opportunity to identify and fund sub-recipient communities throughout Illinois to utilize the SPF model (shown below) to target the most pressing contributing factors to underage drinking using a mix of evidence-based programs, policies and practices based on their local cultural context.
The SPF-PFS project officially concluded activities on September 29, 2019 after five years of funding. Five sites were granted continuation funding through June 30, 2020. These reports are the final reports from this project.
5 year project report:
SPF-PFS Final Evaluation Report, October 2019
Report from the five continuation SPF-PFS sites:
SPF-PFS Evaluation Report July 2020 Addendum
Illinois is experiencing both an opioid overdose epidemic and the COVID-19 pandemic. The numbers of fatal opioid overdoses have increased since 2019 with treatment and harm reduction services complicated by the ongoing COVID-19 pandemic. The goal of this publication is to provide a brief update on the state of the opioid epidemic in Illinois during the COVID-19 pandemic. The 2020 fatality data are provisional, and numbers may change as cases are reviewed and only available through the third quarter of 2020.
A PDF of this report :
Illinois Opioid Overdose Epidemic during the Covid-19 Pandemic
A link to the IDPH website for this report and more information is here
The Medicaid 1115 Substance Use Disorder Demonstration waiver will introduce a limited piloting of certain services that are currently not directly available to Illinois Medicaid beneficiaries. These additional services are expected to inform the state’s efforts to transform the behavioral health system in Illinois as some beneficiaries will have access to less costly community-based services, which are expected to help beneficiaries improve their health and avoid costlier services provided in an institution. The demonstration period is July 1, 2018 through June 30, 2023 and includes 10 pilots addressing inpatient treatment, clinically managed withdrawal, case management, peer recovery support, crisis intervention, home visiting, community integration, supported employment, intensive in-home, and respite services. The project has six goals:
- Increased rates of identification, initiation, and engagement in treatment;
- Increased adherence to and retention in treatment;
- Reductions in overdose deaths, particularly those due to opioids;
- Reduced utilization of emergency departments and inpatient hospital settings for treatment where the utilization is preventable or medically inappropriate through improved access to other continuum of care services;
- Fewer readmissions to the same or higher level of care where the readmission is preventable or medically inappropriate; and
- Improved access to care for physical health and behavioral health conditions among beneficiaries.
The Center for Prevention Research and Development (CPRD) will be conducting an overall evaluation of these pilot services using Interrupted Time Series to compare trend data pre- and post-wavier and individual pilot evaluations using Propensity Score Matching analyses to compare groups. The evaluation will be conducted in partnership with the Office of Medicaid Innovation at the University of Illinois and funded by the Illinois Department of Healthcare and Family Services.
The Illinois Department of Public Health (IDPH) PRAMS project is an ongoing survey of women who recently delivered live born infants in Illinois. PRAMS collects state-level, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy.
From April to December 2019, a 13-question opioid supplement was added to the PRAMS survey. These results are for those responding during April through August 2019 (n=527) and weighted using the corresponding five-month sampling frame.
In addition, from December 2017 through March 2019, a 12-question marijuana and drug use supplement was added to the PRAMS survey. These results are for the calendar year 2018 births. During 2018, a total of 2,175 recent mothers were sampled and 1,306 completed the PRAMS survey (weighted response rate 61%).
Detailed data tables and charts are available at:
2019 Maternal Opioid Use Fact Sheet_12-24-2020
Maternal Marijuana Use Fact Sheet 2018_1-19-2021
A study conducted by the Illinois Department of Public Health, identifies trends in perinatal Electronic Vapor Product usage. Electronic vapor products (EVPs) comprise a diverse group of devices, including electronic cigarettes (e-cigarettes). EVP users inhale an aerosol that typically contains nicotine, flavorings, and other additives. Nicotine is a developmental toxicant that adversely affects pregnancy and infant outcomes. Therefore, EVPs are not safe for mother or baby during pregnancy.
2016-2018 PRAMS_E Vapor Product Use
For more information about various studies conducted by the Illinois Department of Public Health (IDPH) visit the following link: